You just read:

CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion

News provided by

Daiichi Sankyo Company

Jul 17, 2017, 03:00 ET